Pretransplant FLT3-ITD levels predict outcome after allogeneic hematopoietic cell transplantation for AML patients in the first remission

Bone Marrow Transplant. 2020 Apr;55(4):821-823. doi: 10.1038/s41409-019-0576-3. Epub 2019 May 30.

Authors

Li Wan^#¹, Mingzhu Xu^#¹, Jia Chen^#¹, Zuyi Yang^#¹, Mimi Xu¹, Hongjie Shen¹, Xiaojin Wu¹, Shengli Xue¹, Xiao Ma¹, Yue Han¹, Xiaowen Tang¹, Huiying Qiu¹, Depei Wu², Yuejun Liu³

Affiliations

¹ The First Affiliated Hospital of Soochow University, Suzhou, China.
² The First Affiliated Hospital of Soochow University, Suzhou, China. wudepei@medmail.com.cn.
³ The First Affiliated Hospital of Soochow University, Suzhou, China. liuyuejun@suda.edu.cn.

^# Contributed equally.

PMID: 31147598
DOI: 10.1038/s41409-019-0576-3

No abstract available

Publication types

Letter

MeSH terms

Hematopoietic Stem Cell Transplantation*
Humans
Leukemia, Myeloid, Acute* / therapy
Mutation
Remission Induction
Transplantation, Homologous
fms-Like Tyrosine Kinase 3 / genetics

Substances

FLT3 protein, human
fms-Like Tyrosine Kinase 3